Preprint
Review

Are Mitochondria a Target for Treating β-Thalassemia?

Submitted:

28 December 2024

Posted:

30 December 2024

You are already at the latest version

Abstract
The inherited genetic disorder β-thalassemia affects the hematopoietic system and is caused by low production or absence of adult hemoglobin (HbA). Ineffective erythropoiesis is the hallmark of β-thalassemia pathophysiology and is characterized by an erythropoietin-driven substantial increase in erythroblast proliferation, coupled with an increase in late-stage precursor apoptosis, which results in low levels of circulating mature red blood cells (RBCs) and chronic anemia. Mitochondrial dysfunction commonly occurs in these cells because of the increased demand for energy production and the need to manage abnormal hemoglobin chain synthesis. Moreover, several studies have highlighted the importance of gradual mitochondrial clearance for mature erythroid cell production. In this review, we presented the available information on the role of mitochondria in vital cellular processes, which makes them promising pharmacological targets for maintaining the health and function of RBCs.
Keywords: 
Subject: 
Medicine and Pharmacology  -   Hematology
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Alerts
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

© 2025 MDPI (Basel, Switzerland) unless otherwise stated